21.04.2021 Geratherm Medical AG  DE0005495626

DGAP-News: Geratherm Medical AG: Stepping back


 

DGAP-News: Geratherm Medical AG / Key word(s): Personnel
Geratherm Medical AG: Stepping back

21.04.2021 / 12:03
The issuer is solely responsible for the content of this announcement.


Corporate News

Geratal, 21 April 2021

Stepping back

Geratherm Medical AG: Mr. Rudolf Bröcker, Chairman of the Supervisory Board of Geratherm Medical AG, has informed us that he will step back from his position on the Supervisory Board at the end of the Annual General Meeting on June 11, 2021.

Dr. Frank, member of the board of Geratherm Medical AG, has also informed us that he will step back from his position as board member of the company at the end of the general meeting on June 11, 2021. GMF Capital GmbH, which holds more than 25% of the voting rights in the company, proposes the election of Dr. Gert Frank to the Supervisory Board at the Annual General Meeting on June 11, 2021.

Geratherm Medical AG

Investor Relations

Geratherm Medical AG
Fahrenheitstraße 1
99331 Geratal
Phone: +49 (0)36205 98 111
Fax: +49 (0)36205 98-115
E-Mail: [email protected]
Web: www.geratherm.com

Firmensitz: Fahrenheitstraße 1, 99331 Geratal / GERMANY
Vorstand: Dr. Gert Frank (Vorsitzender), Dipl.-Kfm. Christian Frick
Aufsichtsratsvorsitzender: Dipl.-Kfm. Rudolf Bröcker
Registergericht: Amtsgericht Jena HRB 111 272

Short company profil:
Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MRI Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index.




Contact:
Dr. Gert Frank


21.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Geratherm Medical AG
Fahrenheitstraße 1
99331 Geratal
Germany
Phone: +49 (0)36205 98-0
Fax: +49 (0)36205 98-1 15
E-mail: [email protected]
Internet: www.geratherm.com
ISIN: DE0005495626
WKN: 549562
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1187189

 
End of News DGAP News Service

1187189  21.04.2021 

fncls.ssp?fn=show_t_gif&application_id=1187189&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 21,03 21,52 19,85 27,47 23,94 25,85 20,96
EBITDA1,2 1,77 2,80 2,35 4,35 2,31 3,55 4,27
EBITDA-Marge3 8,42 13,01 11,84 15,84 9,65 13,73
EBIT1,4 0,63 1,99 1,05 3,04 0,59 2,07 2,55
EBIT-Marge5 3,00 9,25 5,29 11,07 2,46 8,01 12,17
Jahresüberschuss1 0,22 0,83 0,29 1,90 0,33 1,08 1,67
Netto-Marge6 1,05 3,86 1,46 6,92 1,38 4,18 7,97
Cashflow1,7 2,47 1,35 1,54 3,92 0,92 2,79 1,47
Ergebnis je Aktie8 0,14 0,23 0,11 0,41 0,02 0,19 0,21
Dividende8 0,47 0,40 0,25 0,40 0,12 0,15 0,50
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
Geratherm Medical
WKN Kurs in € Einschätzung Börsenwert in Mio. €
549562 3,320 Verkaufen 17,97
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
15,81 27,16 0,57 16,52
KBV KCV KUV EV/EBITDA
0,82 12,21 0,86 4,09
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,15 0,10 3,01 16.08.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 15.08.2024 - 20.06.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-18,77% -24,11% -38,52% -40,71%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Geratherm Medical AG  ISIN: DE0005495626 können Sie bei EQS abrufen


Medtech , 549562 , GME , XETR:GME